[1] 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021)[J].临床肝胆病杂志, 2022, 38(1): 42-49. DOI: 10.3969/j.issn.1001-5256.2022.01.008. [2] LIU Y, HAO H Q, HOU T Z. Concanavalin A-induced autoimmune hepatitis model in mice: mechanisms and future outlook[J]. Open Life Sci,2022, 17(1): 91-101. DOI: 10.1515/biol-2022-0013. [3] 潘瑞艳,金鸣.羟基红花黄色素A药理作用及机制研究进展[J].中国医药, 2015, 10(8): 1238-1241. DOI: 10.3760/cma.j.issn.1673-4777.2015.08.043. [4] MIN F, SUN H Q, WANG B, et al. Hepatoprotective effects of hydroxysafflor yellow A in D-galactose-treated aging mice[J]. Eur J Pharmacol, 2020, 881: 173214. DOI: 10.1016/j.ejphar.2020.173214. [5] LIU J, MA Z, LI H, et al. Chinese medicine in the treatment of autoimmune hepatitis: progress and future opportunities[J].Animal Model Exp Med, 2022, 5(2): 95-107. DOI: 10.1002/ame2.12201. [6] TANAKA A. Autoimmune hepatitis: 2019 update[J]. Gut Liver, 2020, 14(4): 430-438. DOI: 10.5009/gnl19261. [7] 王璇,赵艳超,吴璇,等.个体化护理干预对自身免疫性肝炎患者临床指标及心理状态的影响[J].北京医学, 2022, 44(10): 953-955, 957. DOI: 10.15932/j.0253-9713.2022.10.020. [8] AO H, FENG WW, PENG C. Hydroxysaffloryellow A: a promising therapeutic agent for a broad spectrum of diseases[J]. Evid Based Complement Alternat Med, 2018, 2018: 8259280. DOI: 10.1155/2018/8259280. [9] 张华敏,刘娜,邓巧娟.羟基红花黄色素A对非酒精性脂肪肝炎细胞的作用[J].中医药导报, 2021, 27(3): 9-12, 22. DOI: 10.13862/j.cnki.cn43-1446/r.2021.03.003. [10] FENG Z, ZHOU P, WU X, et al. Hydroxysafflor yellow A protects against ulcerative colitis via suppressing TLR4/NF-κB signaling pathway[J]. Chem Biol Drug Des, 2022, 99(6): 897-907. DOI: 10.1111/cbdd.14045. [11] ZHANG Y Y, LI L Y, QI C, et al. Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25[J]. Biomed Pharmacother, 2019, 110: 692-699. DOI: 10.1016/j.biopha.2018.12.025. [12] MARESHM M, ABDELAZIZR R, IBRAHIMT M. Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1β, TNF-α, neutrophil infiltration, and apoptosis in mice[J]. Life Sci, 2020, 260: 118307. DOI: 10.1016/j.lfs.2020.118307. [13] LOUIS H, LE MOINE A, QUERTINMONT E, et al. Repeated concanavalin achallenge in mice induces an interleukin 10-producing phenotype and liver fibrosis[J].Hepatology, 2000, 31(2): 381-390. DOI: 10.1002/hep.510310218. [14] 李振亚.血清AST、ALT、ESR及IL-21预测系统性红斑狼疮肝损伤的价值[J].罕少疾病杂志, 2024, 31(4): 57-59.DOI: 10.3969/j.issn.1009-3257.2024.4.023. [15] HAO J H, SUN W L, XU H C. Pathogenesis of Concanavalin A induced autoimmune hepatitis in mice[J]. Int Immunopharmacol, 2022, 102: 108411. DOI: 10.1016/j.intimp.2021.108411. [16] YAN F L, CHENG D L, WANG H Y, et al. Corilaginameliorates con A-induced hepatic injury by restricting M1 macrophage polarization[J]. Front Immunol, 2022, 12: 807509. DOI: 10.3389/fimmu.2021.807509. [17] REN M Q, ZHANG M Y, ZHANG X Y, et al. Hydroxysaffloryellow A inhibits Aβ1-42-induced neuroinflammation by modulating the phenotypic transformation of microglia via TREM2/TLR4/NF-κB pathway in BV-2 cells[J]. Neurochem Res, 2022, 47(3): 748-761. DOI: 10.1007/s11064-021-03484-x. [18] SUNC Y, PEIC Q, ZANGB X, et al. The ability of hydroxysafflor yellow a to attenuate lipopolysaccharide-induced pulmonary inflammatory injury in mice[J]. Phytother Res, 2010, 24(12): 1788-1795. DOI: 10.1002/ptr.3166. [19] ZHOU D Y, QU Z J, WANG H, et al. The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-γ[J]. Exp Ther Med, 2018, 15(1): 520-526. DOI: 10.3892/etm.2017.5414. [20] WANG J P, WANG P, GUI S Q, et al. Hydroxysaffloryellow A attenuates the apoptosis of peripheral blood CD4+ T lymphocytes in a murine model of sepsis[J]. Front Pharmacol, 2017, 8: 613. DOI: 10.3389/fphar.2017.00613. [21] YANG Z, RAJENDRAN S, SPIRES V, et al. Target-mediated drug disposition affects the pharmacokinetics of interleukin-10 fragment crystallizable fusion proteins at pharmacologically active doses[J]. Drug Metab Dispos,2022, 50(7): 898-908. DOI: 10.1124/dmd.121.000799. |